[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633883":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":39,"collaborators":41,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":7,"enrollmentInfo":55,"targetDuration":7,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":7,"overallStatus":62,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"The Royal Wolverhampton Hospitals NHS Trust","OTHER_GOV",null,[9],{"name":10,"affiliation":11,"role":12},"Hannah Giles","University Hospital Birmingham NHS Foundation Trust","PRINCIPAL_INVESTIGATOR",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Tanweer Ahmed","CONTACT","01902 695065","rwh-tr.ukchart@nhs.net",{"name":20,"role":16,"phone":7,"phoneExt":7,"email":21},"Lorraine Jacques","rwh-tr.sponsorshipofresearch@nhs.net",[23],{"facility":24,"status":7,"city":25,"state":7,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"The Royal Wolverhampton NHS Trust","Wolverhampton","WV10 0QP","United Kingdom","UK",{"type":30,"coordinates":31},"Point",[32,33],-2.12296,52.58547,{"lat":33,"lon":32},[36,37,38],{"name":15,"role":16,"phone":7,"phoneExt":7,"email":18},{"name":20,"role":16,"phone":7,"phoneExt":7,"email":21},{"name":10,"role":12,"phone":7,"phoneExt":7,"email":7},{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[42],{"name":43,"class":44},"Johnson & Johnson","INDUSTRY","100633883","real-world-maia-uk-outcomes-100633883",false,"NCT07532473","REal World MAIA UK OutcomEs","A Retrospective Study of Clinical Outcomes in Newly Diagnosed, Transplant Ineligible Multiple Myeloma Patients Treated With Daratumumab, Lenalidomide and Dexamethasone (DRd) Outside of Clinical Trials in the UK","REMAKE","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of NDMM\n* Not eligible for autologous stem cell transplant at diagnosis\n* Received frontline DRd treatment following NICE approval (post-September 2023)\n* Minimum 3 months of follow-up data available\n\nExclusion Criteria:\n\n* Participation in an interventional clinical trial for first-line therapy\n* Insufficient treatment or follow-up data for analysis\n* DRd used in relapsed\u002Frefractory setting rather than newly diagnosed disease","ALL","18 Years",{"count":56,"type":57},300,"ESTIMATED","OBSERVATIONAL","This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.",[61],"Myeloma","NOT_YET_RECRUITING","2026-04-15",{"date":65,"type":66},"2026-04-20","ACTUAL",{"date":68,"type":57},"2026-07",{"date":70,"type":57},"2028-07",{"name":5,"class":6},1]